Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities
Net (loss) income	$ (679)	$ 10,088
Adjustments to reconcile net income to net cash from operating activities:
Gain on foregivness of PPP loan	0	(6,604)
Depreciation and amortization	23,930	11,436
Goodwill and intangible assets impairment expense	0	1,081
Amortization of deferred loan fees and line of credit fees	394	79
Amortization of label design fees	973	464
Litigation proceeds	(3,000)	(4,750)
Stock-based compensation expense	6,915	3,334
Provision for doubtful accounts	(22)	48
Impairment of inventory	3,667	3,302
Inventory write down	15,433	0
Remeasurement of contingent consideration liabilities	(3,570)	(329)
Net unrealized gain on interest rate swap agreements	(22,950)	(6,136)
Provision for deferred income tax	981	851
Loss (gain) on disposition of assets	485	(1,001)
Deferred gain on sale leaseback	(1,334)	(1,335)
Noncash interest expense	0	68
Deferred rent	375	352
Change in operating assets and liabilities (net of effect of business combinations):
Accounts receivable	(13,183)	(3,137)
Related party receivables	0	325
Other receivables	3,624	(4,456)
Litigation receivable	3,000	4,750
Inventories	18,075	2,311
Prepaid expenses and other current assets	(4,656)	(4,115)
Other assets	(2,464)	1,498
Accounts payable	(7,795)	(4,983)
Accrued liabilities and other payables	(2,217)	8,191
Related party liabilities	0	(2,215)
Net cash provided by operating activities	15,982	9,117
Cash flows from investing activities
Proceeds from disposition of assets	153	1,044
Purchases of property, plant, and equipment	(24,835)	(38,032)
Label design expenditures	(143)	(492)
Proceeds on related party notes receivable	0	756
Acquisition of businesses	(73,680)	(23,564)
Net cash used in investing activities	(98,505)	(60,288)
Cash flows from financing activities
Principal payments on line of credit	(144,706)	(181,411)
Proceeds from line of credit	201,570	106,217
Outstanding checks in excess of cash	1,759	2,509
Purchase of Series B redeemable stock	0	(32,000)
Settlement of stock options	0	(7,944)
Borrowings on long-term debt	0	76,067
Loan fees	0	(492)
Principal payments on long-term debt	(22,763)	(28,374)
Merger and PIPE financing, net of transaction costs	0	250,126
Principal payments on related party debt	0	(10,000)
Debt issuance costs	0	(918)
Repurchase of common stock	(26,034)	0
Repurchase of public warrants	(270)	0
Payments on acquisition payable	(420)	(681)
Net cash provided by financing activities	9,136	173,099
Net change in cash and restricted cash	(73,387)	121,928
Cash and restricted cash, beginning of year	123,679	1,751
Cash and restricted cash, end of year	50,292	123,679
Cash paid during the period for:
Interest	13,199	13,373
Income taxes	23	222
Noncash investing and financing activities:
Accretion Series A	0	156,467
Accretion Series B	0	5,785
Conversion of promissory note to common stock	0	4,818
Contingent consideration in business combinations	8,534	4,000
Issuance of common stock in business combination	10,521	0
Issuance of Series A stock in a business combination	0	25,831
Notes payable for acquisition of business	$ 0	$ 11,668